10-Q: Bionano Genomics Q3 2025: Losses Narrow, Cash Concerns Persist

Bionano Genomics reported a significant reduction in net loss for Q3 2025, driven by cost-saving initiatives, but acknowledged substantial doubt about its ability to continue as a going concern without further capital.

Summary

• Net loss for the three months ended September 30, 2025, was $(8.5) million, an 81% improvement from $(44.2) million in the same period of 2024.
• Net loss for the nine months ended September 30, 2025, was $(18.5) million, an 80% improvement from $(91.9) million in the same period of 2024.
• Total revenue for Q3 2025 increased by 21% to $7.4 million, compared to $6.1 million in Q3 2024.
• Total revenue for the nine months ended September 30, 2025, decreased by 9% to $20.6 million, compared to $22.6 million in the same period of 2024.
• Product revenue for Q3 2025 increased by 15% to $6.9 million, driven by increases in instrument, consumables, and software sales.
• Product revenue for the nine months ended September 30, 2025, decreased by 1% to $19.2 million, with instrument sales down 30%, partially offset by increases in consumables and software sales.
• Service and other revenue for the nine months ended September 30, 2025, decreased by 60% to $1.3 million, primarily due to the discontinuation of certain clinical service offerings from Bionano Laboratories.
• Gross profit for Q3 2025 was $3.4 million, a 140% increase from $(8.4) million in Q3 2024, largely due to the absence of significant inventory write-offs and reagent rental disposition expenses seen in the prior year.
• Cash used in operating activities decreased substantially to $12.2 million for the nine months ended September 30, 2025, from $62.4 million in the same period of 2024.
• The installed base of OGM systems grew by 4% year-over-year to 384 units as of September 30, 2025.
• Flowcells sold increased by 7% in Q3 2025 to 8,390 units and by 2% for the nine months ended September 30, 2025, to 22,617 units.
• As of September 30, 2025, the company had $3.1 million in cash and cash equivalents, $18.5 million in short-term investments, and $10.3 million in restricted short-term investments.
• The accumulated deficit stood at $711.7 million as of September 30, 2025.
• Management has identified substantial doubt about the company's ability to continue as a going concern within 12 months without raising additional funding.
• The company completed a 1-for-60 reverse stock split on January 24, 2025.
• Approximately $29.3 million in gross proceeds were raised from sales of common stock and warrants through registered direct offerings and at-the-market facilities during the nine months ended September 30, 2025.

Sentiment

Score: 3

Explanation: The company continues to face substantial financial challenges, including recurring net losses, negative cash flows, and an accumulated deficit, leading to a 'going concern' warning. While cost-saving measures have reduced losses and operating cash burn, revenue growth has slowed, and significant capital raises are still required to sustain operations. The long-term viability remains highly dependent on future financing and market acceptance.

Positives

• Net loss significantly reduced by 81% in Q3 2025 and 80% for the nine months ended September 30, 2025, compared to the prior year, primarily due to cost-saving initiatives and reduced impairment charges.
• Total revenue increased by 21% in Q3 2025 compared to Q3 2024, driven by growth in instrument, consumables, and software sales.
• Product gross profit increased substantially by 138% in Q3 2025 and 305% for the nine months ended September 30, 2025, benefiting from the absence of large inventory write-offs and reagent rental disposition expenses incurred in the prior year.
• Operating expenses, including Research and Development and Selling, General and Administrative, decreased significantly for both the three-month and nine-month periods, reflecting successful cost-saving initiatives and workforce reductions.
• Cash used in operating activities decreased substantially to $12.2 million for the nine months ended September 30, 2025, from $62.4 million in the same period of 2024.
• The installed base of OGM systems grew by 4% year-over-year to 384 units, indicating continued adoption of the technology.
• Flowcells sold increased by 7% in Q3 2025 and 2% for the nine months ended September 30, 2025, demonstrating ongoing utilization of OGM consumables.
• The company successfully raised approximately $29.3 million in gross proceeds through equity offerings and ATM sales during the nine months ended September 30, 2025, providing additional liquidity.
• A $2.1 million Employee Retention Credit (ERC) refundable tax credit was received during the nine months ended September 30, 2025.

Negatives

• The company has incurred recurring net losses from operations and negative cash flows since its inception, with a significant accumulated deficit of $711.7 million as of September 30, 2025.
• Management has identified substantial doubt about the company's ability to continue as a going concern within 12 months without securing additional funding.
• Total revenue for the nine months ended September 30, 2025, decreased by 9% year-over-year, primarily due to a 60% decline in service and other revenue from discontinued clinical service offerings.
• Product revenue for the nine months ended September 30, 2025, saw a slight decrease of 1%, with instrument sales down 30%, indicating challenges in new system placements.
• The change in business strategy to focus on existing OGM installed base utilization, with less emphasis on new placements, is expected to slow the pace of revenue growth for the remainder of 2025.
• Cash and cash equivalents decreased to $3.1 million as of September 30, 2025, from $9.2 million at December 31, 2024.
• Interest income decreased by 29% in Q3 2025 and 55% for the nine months ended September 30, 2025, due to a reduction in investments.
• The company expects to continue to incur significant expenses and operating losses into the foreseeable future.
• Existing stockholders have experienced dilution from multiple equity offerings and warrant issuances.
• Servicing convertible debentures requires significant cash, with $10.3 million principal outstanding as of September 30, 2025, and expected payments of $4.1 million principal and $0.3 million interest for the remainder of 2025.
• The company's public float is less than $75 million, limiting its ability to raise capital using Form S-3 shelf registration statements to one-third of its public float in any 12-month period.
• The reverse stock split may not achieve all intended results, and the market price of the common stock may be negatively impacted.

Risks

• Recurring net losses and negative cash flows raise substantial doubt about the ability to continue as a going concern, requiring additional capital that may not be available on acceptable terms, if at all.
• Corporate cost-saving initiatives and associated headcount reductions could disrupt business, lead to loss of institutional knowledge, reduced sales force strength, decreased morale, and may not achieve intended objectives.
• Limited commercial history as an early commercial-stage company makes it difficult to evaluate current business and predict future performance, especially with evolving business models and fluctuating operating costs.
• Quarterly and annual operating results and cash flows have fluctuated and may continue to fluctuate, making future operating results difficult to predict and potentially causing stock price decline.
• Future capital needs are uncertain, and additional funding will be required to advance commercialization and R&D; failure to obtain sufficient funding could delay, reduce, or eliminate significant efforts.
• Terms of the Debentures and Debenture Purchase Agreement restrict current and future operations, and an event of default could prevent accelerated payments.
• Unfavorable geopolitical and macroeconomic developments (e.g., inflation, bank failures, conflicts in Ukraine/Russia and Middle East, trade policies) could adversely affect business, financial condition, or results of operations.
• Acquisitions, joint ventures, and other strategic transactions could disrupt or harm the business and cause dilution to stockholders, with integration challenges and potential for unforeseen expenses or liabilities.
• Failure of products or technologies to achieve and sustain sufficient market acceptance will adversely affect revenue, as potential customers may be reluctant to replace existing systems.
• Near-term sales depend on R&D spending by clinical research laboratories, academic/governmental institutions, and biopharmaceutical companies; reductions in such spending could limit demand.
• Failure to successfully manage the development and launch of new products and technologies could adversely affect financial results.
• Future success depends on the ability to further penetrate the existing customer base, attract new customers, and retain customers of acquired businesses.
• The size of markets for products and technologies may be smaller than estimated, and new markets may not develop as quickly as expected, limiting sales ability.
• Current limitation to Research Use Only (RUO) for many materials and components; if products are deemed medical devices or marketed for clinical diagnostic use, regulatory clearance/approval would be required, which is expensive, time-consuming, and uncertain.
• Subject to stringent and evolving U.S. and foreign laws, regulations, and rules related to data privacy and security; non-compliance could lead to investigations, litigation, fines, and business disruption.
• Highly competitive life sciences research and diagnostic markets; failure to compete effectively could harm business.
• Failure to comply with environmental, health, and safety laws and regulations could result in fines or penalties.
• Reliance on a single contract manufacturer for OGM systems and a limited number for chip consumables; failure of these manufacturers could negatively affect supply.
• Undetected errors or defects in products or technologies could harm reputation, decrease market acceptance, or expose the company to product liability claims or recalls.
• Reliance on distributors for international sales; inadequate performance or inability to secure partners could limit sales and revenue.
• Expectation to generate a substantial portion of revenue internationally, subject to various risks related to international activities (e.g., regulatory, currency, political instability).
• Inability to recruit, train, retain, motivate, and integrate key personnel may prevent achievement of goals.
• Inability to provide quality technical and applications support could lead to customer loss.
• Billing for Bionano Laboratories diagnostic testing procedures is complex and requires substantial time and resources to collect payment.
• Bionano Laboratories diagnostic testing procedures are subject to unfavorable pricing regulations or third-party payor coverage and reimbursement policies, which could harm the business.
• Healthcare legislative or regulatory reform measures may negatively impact business and results of operations.
• Compliance with numerous regulations is expensive and time-consuming; failure to comply could result in substantial penalties.
• Subject to federal and state healthcare fraud and abuse laws and other laws applicable to business activities; non-compliance could lead to substantial penalties.
• Subject to governmental export and import controls; non-compliance could impair ability to compete and lead to liability.
• Inability to protect intellectual property may reduce ability to maintain technological or competitive advantage.
• Rights in some intellectual property discovered through government-funded programs are subject to federal regulations (e.g., march-in rights, reporting requirements, U.S. industry preference), which may limit exclusive rights.
• Dependence on intellectual property licensed from third parties; loss of rights or inability to enter necessary licenses could have an adverse impact.
• Lawsuits for infringing third-party intellectual property rights would be costly and time-consuming, with potentially unfavorable outcomes.
• Involvement in lawsuits to protect or enforce patents could be expensive, time-consuming, and unsuccessful.
• Issued patents could be found invalid or unenforceable if challenged.
• Subject to claims that employees, consultants, or independent contractors have wrongfully used or disclosed alleged trade secrets of others, or that others have rights in the company's intellectual property.
• Inability to protect intellectual property rights throughout the world could negatively affect business.
• Changes in patent laws or jurisprudence could diminish the value of patents.
• Obtaining and maintaining patent protection depends on compliance with various procedural requirements; non-compliance could reduce or eliminate protection.
• Inadequate protection of trademarks and trade names could hinder name recognition.
• Use of third-party open-source software components; failure to comply with licenses could restrict ability to sell products.
• Use of third-party software that may be difficult to replace or cause errors/failures.
• Numerous factors may limit any potential competitive advantage provided by intellectual property rights.
• Price of securities has been and may be volatile or decline regardless of operating performance.
• Reverse stock splits may not achieve intended results and could negatively impact market price.
• Effective increase in shares available for issuance due to reverse stock splits could result in further dilution and have anti-takeover implications.
• Failure to comply with Nasdaq listing requirements could lead to delisting.
• Failure to maintain effective internal control over financial reporting could lead to inaccurate financial reports and stock price decline.
• Reduced reporting requirements as a smaller reporting company could make securities less attractive to investors.
• Significant portion of outstanding shares restricted from immediate resale may be sold, causing stock price to drop.
• Anti-takeover provisions could delay or prevent a change of control.
• Exclusive forum provisions in charter documents could limit stockholders' ability to obtain a favorable judicial forum.
• An active trading market for common stock may not be sustained.
• Unsuccessful identification and implementation of strategic alternatives, or negative consequences from consummated transactions.
• If a strategic transaction is not consummated, the board may pursue dissolution and liquidation, with uncertain cash distribution to stockholders.
• Value to stockholders in a strategic transaction or dissolution depends on successfully satisfying existing contractual obligations on favorable terms.
• Securities class action litigation could divert management's attention and harm business.

Future Outlook

Management expects operating losses and negative cash flows to continue for at least the next year as the company incurs costs related to product development and commercialization. The change in business strategy to focus on OGM utilization from the existing installed base, with less emphasis on new placements, is expected to slow the pace of revenue growth for the remainder of 2025. Research and Development (R&D) and Selling, General and Administrative (SG&A) expenses are anticipated to decrease throughout 2025 compared to 2024 due to cost-saving initiatives. Service and other revenue is expected to remain relatively flat in 2025 as clinical service offerings were fully phased out by December 31, 2024. The company believes its current cash, cash equivalents, and short-term investments, along with recent financings, will fund operations into the third quarter of 2026, but additional capital will be required to achieve cash-flow break-even.

Management Comments

• "Management expects operating losses and negative cash flows to continue for at least the next year as the Company continues to incur costs related to product development and commercialization efforts."
• "Managements ability to continue as a going concern is dependent upon its ability to raise additional funding."
• "Management has prepared cash flows forecasts which indicate that based on the Companys expected operating losses and negative cash flows, there is substantial doubt about the Companys ability to continue as a going concern within 12 months after the date that the unaudited condensed consolidated financial statements for the nine months ended September 30, 2025, are issued."
• "We expected that this change in strategy [focus on existing OGM installed base] would slow the pace of our revenue growth when compared to historical growth rates, and we anticipate that the reduced pace of our revenue growth will continue in the remainder of 2025."
• "We expect cost of product revenue to fluctuate with the volume of product sales."
• "We expect cost of service and other revenue to remain relatively flat in 2025 as these service offerings were fully phased out as of December 31, 2024."
• "We anticipate that R&D expenses will decrease throughout 2025, in comparison to the same period in 2024, as a result of our cost saving initiatives announced in March and September 2024."
• "We anticipate that SG&A expenses will decrease throughout 2025, in comparison to the same period in 2024, as a result of our cost saving initiatives announced in March and September 2024."
• "Based on our current business plans, we believe we will be able to fund our operating expenses and capital expenditure requirements into the third quarter of 2026."
• "Our existing cash and cash equivalents and short-term investments will not be sufficient for us to achieve cash-flow break even, and we expect to need to seek additional capital."
• "From time to time, the board of directors maintains a strategy committee to work with the Company and outside advisors in evaluating our options and considering alternatives that we believe will maximize stakeholder value, including any of the following or a combination thereof: debt financing, equity investments, combinations with other companies, or the sale of all or part of the company."

Industry Context

The company operates in the highly competitive life sciences research and diagnostic markets, characterized by rapid technological changes and frequent new product introductions. Its optical genome mapping (OGM) solutions compete with established technologies like karyotyping and FISH, as well as other genome analysis platforms from companies like Nabsys, PacBio, and Oxford Nanopore Technologies. The shift in business strategy to focus on existing OGM installed base utilization rather than new placements reflects a potential maturation or strategic pivot within the OGM market, possibly in response to competitive pressures or market adoption rates. The macroeconomic and geopolitical developments, including inflation and supply chain disruptions, are noted as ongoing challenges impacting the broader industry, particularly affecting government funding reliant partners in the Asia Pacific region. The company's efforts to reduce operating expenses through workforce reductions and streamline operations are consistent with a challenging economic environment and a focus on efficiency in the biotech sector.

Corporate Governance

Legal Proceedings

• The company currently does not have any material loss exposure as it is not a defendant in any material claims or legal actions.

Stakeholder Impact

• Shareholders: Potential for significant dilution from ongoing equity offerings and warrant exercises. Risk of losing all or part of their investment if the company cannot continue as a going concern or if liquidation occurs. Stock price volatility and potential decline due to financial performance and market factors. Anti-takeover provisions could limit their ability to influence corporate control.
• Employees: Headcount reductions (May 2023, October 2023, March 2024, September 2024) have impacted employees, potentially leading to decreased morale, loss of institutional knowledge, and increased workload for remaining staff. Competition for qualified personnel remains intense.
• Customers: Potential for slower revenue growth due to the shift in business strategy focusing less on new OGM system placements. Risk of product delays or disruptions if supply chain issues or manufacturing problems occur. Discontinuation of certain Bionano Laboratories testing services impacts customers who relied on those offerings.
• Suppliers/Contract Manufacturers: Reliance on single or limited suppliers for critical components creates risk if those suppliers fail or do not perform satisfactorily. Weekly deposits for future inventory purchases indicate ongoing commitment but also potential risk if demand changes.
• Creditors: Risk of default on convertible debentures if the company cannot generate sufficient cash flow or raise additional capital. The 'going concern' warning indicates heightened risk for creditors.

Next Steps

• Continue to incur costs related to product development and commercialization efforts.
• Seek additional capital through public or private equity or debt financings to fund operating and capital requirements.
• Further curtail or cease operations and seek bankruptcy protection if unable to raise sufficient additional capital in the very near term.
• Board of directors' strategy committee to continue evaluating options such as debt financing, equity investments, combinations with other companies, or the sale of all or part of the company.
• Continue to evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements and related disclosures for the year ending December 31, 2025.
• Continue to evaluate the impact of ASU 2023-09 (Income Taxes) and ASU 2024-03 (Expense Disaggregation Disclosures) on consolidated financial statements and related disclosures.
• Monitor and comply with various applicable guidelines and legal requirements in jurisdictions of operation, especially regarding macroeconomic and geopolitical developments.
• Continue to make weekly deposits for future inventory purchases through November 21, 2025, under an agreement with the instrument contract manufacturer.
• Monitor the U.S. government shutdown's potential impact on manufacturing partners and customers reliant on government funding, and on product delivery and service.
• File another amendment to the ATM Prospectus if the public float increases above $75.0 million to sell additional amounts under the ATM Agreement.

Key Dates

Recommendation

Despite some operational improvements and cost reductions, the filing explicitly states 'substantial doubt about the Company's ability to continue as a going concern within 12 months' without additional funding. This fundamental risk, coupled with recurring net losses, negative cash flows, and a significant accumulated deficit, overshadows any positive revenue trends or cost savings. While capital raises have occurred, they are dilutive and continuous, indicating an unsustainable operational model without external financing. The shift in business strategy to focus on existing installed base rather than new placements suggests a slowdown in core growth. A seasoned investor would view the going concern warning and continuous need for dilutive capital as a strong signal to exit or avoid the stock due to extreme risk and uncertainty regarding long-term viability and shareholder value preservation.

Keywords

Optical Genome Mapping (OGM), Genome Analysis, Biotechnology, Life Sciences Research, Diagnostic Services, SEC Filing, 10-Q, Financial Results, Liquidity, Going Concern, Capital Raise, Stock Split, Consumables, Software, Research and Development, Cost Savings, Nasdaq